Advertisement

Topics

Latest "Testing Immune Hotspots Predict Risk That Breast Cancer" News Stories

06:35 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "Testing Immune Hotspots Predict Risk That Breast Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Testing Immune Hotspots Predict Risk That Breast Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Testing Immune Hotspots Predict Risk That Breast Cancer for you to read. Along with our medical data and news we also list Testing Immune Hotspots Predict Risk That Breast Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Testing Immune Hotspots Predict Risk That Breast Cancer Companies for you to search.

Showing "Testing Immune Hotspots Predict Risk That Breast Cancer" News Articles 1–25 of 30,000+

Saturday 16th February 2019

Week in Review: CStone's Hong Kong IPO to Raise $304 Million at $1.5 Billion Valuation Next Week

Deals and Financings • CStone Pharma of Suzhou will raise $304 million next week in its Hong Kong IPO at a valuation of $1.5 billion to advance fourteen clinical-stage oncology candidates;• Shanghai HaiHe Biopharma, an oncology company with ten molecules in clinical trials, announced a $146.6 million funding;• Burning Rock Biotech, a Guangzhou diagnostics company, closed a $126 mill...


That's a wrap on #GU19, but our commitment to #InventingForLife continues every single day. See you in June for more discussions on #cancer care at #ASCO19!pic.twitter.com/8mHlYYGSAT

That's a wrap on #GU19, but our commitment to #InventingForLife continues every single day. See you in June for more discussions on #cancer care at #ASCO19! pic.twitter.com/8mHlYYGSAT

Merck, Pfizer drug combo extends kidney cancer survival: study

A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Satu...


KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine Also Showed Risk of Progression or Death Reduced by 31 Percent Data Consistent Across all IMDC Risk Groups and Regardless of PD-L1 Expression Merck (NYSE: MRK), known as MSD ou...

A year in space put astronaut Scott Kelly’s immune system on high alert and changed the activity of some of his genes compared to his Earth-bound identical twin. https://buff.ly/2GRecbT 

A year in space put astronaut Scott Kelly’s immune system on high alert and changed the activity of some of his genes compared to his Earth-bound identical twin. https://buff.ly/2GRecbT 

$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-

$CALA Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at ASCO #GU19 11:35AM PST https://globenewswire.com/news-release/2019/02/16/1733533/0/en/Updated-Results-from-Phase-1-Study-of-Telaglenastat-CB-839-to-be-Presented-at-2019-ASCO-Genitourinary-Cancer-Symposium.html …

Tailored #Cancer Drugs from New Cell Receptor Insights: http://ow.ly/kLvs30nET28 pic.twitter.com/QEVyjQcRoK

Tailored #Cancer Drugs from New Cell Receptor Insights: http://ow.ly/kLvs30nET28  pic.twitter.com/QEVyjQcRoK

AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian Rini, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Di...

Hunt for immunotherapy combinations turns up success in kidney cancer

Drug pairings tested by Merck & Co. and Pfizer proved effective, and could soon compete with Bristol-Myers' combo in metastatic renal cell carcinoma. 

Low physical fitness and obesity during teen years linked to disability later in life

1. This prospective cohort study found that both low physical fitness and obesity during adolescence is associated with increased risk for disability later in life. 2. Obesity during adolescence, measured through body mass index (BMI), was found to be the greatest predictor of all-cause disability later in life for Swedish men. Evidence Rating Level: 1 […] Source: 2 Minute Medicine

Does Eating Organic Reduce Cancer Risk? http://dlvr.it/Qz2bk3 pic.twitter.com/jZMV0XZnik

Does Eating Organic Reduce Cancer Risk? http://dlvr.it/Qz2bk3  pic.twitter.com/jZMV0XZnik

Bispecific, Multispecific Antibodies Grapple with #Cancer -- http://ow.ly/MVLs30nFLo9 pic.twitter.com/fMgyCbYfcS

Bispecific, Multispecific Antibodies Grapple with #Cancer -- http://ow.ly/MVLs30nFLo9  pic.twitter.com/fMgyCbYfcS

. @SGS_SA Expands #Glasgow Facility’s Testing Capabilities: http://ow.ly/igTX30nGILC pic.twitter.com/sRj4rKwEUQ

. @SGS_SA Expands #Glasgow Facility’s Testing Capabilities: http://ow.ly/igTX30nGILC  pic.twitter.com/sRj4rKwEUQ

MRSA Decolonization; Perinatal Depression: It's PodMed Double T! (with audio)

(MedPage Today) -- This week's topics also include active surveillance for prostate cancer and reducing opioid use after hip surgery

Bruno Ganz, actor who played Hitler in Downfall, dies aged 77 – The Guardian

Bruno Ganz, actor who played Hitler in Downfall, dies aged 77 The GuardianBruno Ganz, who played Hitler in Downfall, dies aged 77 BBC NewsBruno Ganz dead at 77: Star who played Adolf Hitler | Daily Star Daily StarBruno Ganz who starred as Hitler in Downfall movie has died aged 77 Daily MailBruno Ganz dead at 77: Actor who played Adolf Hitler in Downfall passes away at home after cancer ba...

EU approves Roche’s atezolizumab for bladder cancer

Targovax drug boosts 2-year OS in pancreatic cancer

Answer: Metastatic HSPC #prostatecancer is a form of advanced prostate #cancer that an estimated 38,000 men will develop per year in the U.S. #GU19

Answer: Metastatic HSPC #prostatecancer is a form of advanced prostate #cancer that an estimated 38,000 men will develop per year in the U.S. #GU19

Smoking and HLA Genes in Rheumatoid Arthritis

(MedPage Today) -- New study sorts out relative contributions of these risk factors

Smoked Alaska Seafoods, Inc. Recalls 6.5 oz Jars & Cans of Smoked Silver Salmon Because of Possible Health Risk

Smoked Alaska Seafoods, Inc. of Wasilla, AK is recalling all jars and cans of Smoked Silver Salmon in 6.5 oz. containers with the production code of AL81111133 on the bottom of the jar/can because it has the potential to be contaminated with Clostridium botulinum, a bacterium which can cause life-threatening illness or death. Consumers are warned not to use the product even if it does not look or ...

News digest – HPV stigma, ultra-processed foods, ‘simple’ cancer blood test and why measles isn’t a cancer cure

Science blog Stigma around HPV infection causes concern Misunderstanding and perceived stigma around the human papillomavirus (HPV) infection is concerningly high and could put women off cervical screening, reports the Independent and others. The results

Friday 15th February 2019

Company Profile for Novus Therapeutics, Inc.

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device co...

ASCO GU 2019: Updates on treatment and management of bladder cancer

Professor Matthew Galsky chairs a discussion with Professor Ananya Choudhury, Professor Joaquim Bellmunt and Dr Andrea Necchi on the latest data presented at ASCO GU 2019 in San Francisco, specifically focused on the treatment and management of urothelial...

ASCO GU 2019: Treatment and management of hormone-sensitive metastatic prostate cancer

Professor Karim Fizazi and Professor Eleni Efstathiou set the scene in current care and discuss the treatment options available for hormone-sensitive metastatic prostate cancer, highlighting the unmet need in recurrent metastatic disease. New updates to...

ASCO GU 2019: Updates on non-metastatic castration-resistant prostate cancer

Professor Karim Fizazi chairs a discussion with Professors Eleni Efstathiou, Nicholas Mottet, and Boris Hadaschek on the latest data presented at ASCO GU 2019 in San Francisco, specifically focused on patients with non-metastatic CRPC. The group...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks